Literature DB >> 29274756

Different Causes of Death in Patients with Myocardial Infarction Type 1, Type 2, and Myocardial Injury.

Sascha Lambrecht1, Laura Sarkisian1, Lotte Saaby1, Tina S Poulsen1, Oke Gerke2, Susanne Hosbond1, Axel C P Diederichsen1, Kristian Thygesen3, Hans Mickley4.   

Abstract

BACKGROUND: Data outlining the mortality and the causes of death in patients with type 1 myocardial infarction, type 2 myocardial infarction, and those with myocardial injury are limited.
METHODS: During a 1-year period from January 2010 to January 2011, all hospitalized patients who had cardiac troponin I measured on clinical indication were prospectively studied. Patients with at least one cardiac troponin I value >30 ng/L underwent case ascertainment and individual evaluation by an experienced adjudication committee. Patients were classified as having type 1 myocardial infarction, type 2 myocardial infarction, or myocardial injury according to the criteria of the universal definition of myocardial infarction. Follow-up was ensured until December 31, 2014. Data on mortality and causes of death were obtained from the Danish Civil Registration System and the Danish Register of Causes of Death.
RESULTS: Overall, 3762 consecutive patients were followed for a mean of 3.2 years (interquartile range 1.3-3.6 years). All-cause mortality differed significantly among categories: Type 1 myocardial infarction 31.7%, type 2 myocardial infarction 62.2%, myocardial injury 58.7%, and 22.2% in patients with nonelevated troponin values (log-rank test; P < .0001). In patients with type 1 myocardial infarction, 61.3% died from cardiovascular causes, vs 42.6% in patients with type 2 myocardial infarction (P = .015) and 41.2% in those with myocardial injury (P < .0001). The overall mortality and the causes of death did not differ substantially between patients with type 2 myocardial infarction and those with myocardial injury.
CONCLUSIONS: Patients with type 2 myocardial infarction and myocardial injury exhibit a significantly higher long-term mortality compared with patients with type 1 myocardial infarction . However, most patients with type 1 myocardial infarction die from cardiovascular causes in contrast to patients with type 2 myocardial infarction and myocardial injury, in whom noncardiovascular causes of death predominate.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Causes of death; Myocardial injury; Troponin; Type 1 myocardial infarction; Type 2 myocardial infarction

Mesh:

Substances:

Year:  2017        PMID: 29274756     DOI: 10.1016/j.amjmed.2017.11.043

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  13 in total

1.  Assessment of Oxygen Supply-Demand Imbalance and Outcomes Among Patients With Type 2 Myocardial Infarction: A Secondary Analysis of the High-STEACS Cluster Randomized Clinical Trial.

Authors:  Anda Bularga; Caelan Taggart; Filip Mendusic; Dorien M Kimenai; Ryan Wereski; Matthew T H Lowry; Kuan K Lee; Amy V Ferry; Stacey S Stewart; David A McAllister; Anoop S V Shah; Atul Anand; David E Newby; Nicholas L Mills; Andrew R Chapman
Journal:  JAMA Netw Open       Date:  2022-07-01

2.  Risk factors for type 1 and type 2 myocardial infarction.

Authors:  Ryan Wereski; Dorien M Kimenai; Anda Bularga; Caelan Taggart; David J Lowe; Nicholas L Mills; Andrew R Chapman
Journal:  Eur Heart J       Date:  2022-01-13       Impact factor: 35.855

3.  Wake Forest University long-term follow-up of type 2 myocardial infarction: The Wake-Up T2MI Registry.

Authors:  Hanumantha R Jogu; Sameer Arora; Muthiah Vaduganathan; Arman Qamar; Ambarish Pandey; Parag A Chevli; Tusharkumar H Pansuriya; Muhammad I Ahmad; Abhishek Dutta; Padageshwar R Sunkara; Waqas Qureshi; Sujethra Vasu; Bharathi Upadhya; Deepak L Bhatt; James L Januzzi; David Herrington
Journal:  Clin Cardiol       Date:  2019-04-12       Impact factor: 2.882

4.  A systematic review on the triggers and clinical features of type 2 myocardial infarction.

Authors:  Guangqiang Wang; Na Zhao; Shu Zhong; Jianping Li
Journal:  Clin Cardiol       Date:  2019-07-11       Impact factor: 2.882

5.  Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.

Authors:  Harvey D White; Ph Gabriel Steg; Michael Szarek; Deepak L Bhatt; Vera A Bittner; Rafael Diaz; Jay M Edelberg; Andrejs Erglis; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Renato D Lopes; Kenneth W Mahaffey; Angele Moryusef; Robert Pordy; Matthew T Roe; Piyamitr Sritara; Pierluigi Tricoci; Andreas M Zeiher; Gregory G Schwartz
Journal:  Eur Heart J       Date:  2019-09-01       Impact factor: 29.983

Review 6.  Assessment and Treatment of Patients With Type 2 Myocardial Infarction and Acute Nonischemic Myocardial Injury.

Authors:  Andrew P DeFilippis; Andrew R Chapman; Nicholas L Mills; James A de Lemos; Armin Arbab-Zadeh; L Kristin Newby; David A Morrow
Journal:  Circulation       Date:  2019-08-16       Impact factor: 29.690

Review 7.  Type 2 myocardial infarction: a diagnostic and therapeutic challenge in contemporary cardiology.

Authors:  Andrea Carlo Merlo; Roberta Della Bona; Pietro Ameri; Italo Porto
Journal:  Intern Emerg Med       Date:  2022-02-14       Impact factor: 5.472

8.  Clinical characteristics and outcome of elderly patients admitted in emergency department with an oxygen mismatch and type 2 myocardial infarction or myocardial injury.

Authors:  Laurent Jacquin; Nathan Mewton; Stéphanie Bosne; Adrien Mantout; Cyrille Bergerot; Karim Tazarourte; Marion Douplat
Journal:  Aging Clin Exp Res       Date:  2021-07-11       Impact factor: 3.636

Review 9.  Diagnosis, Investigation and Management of Patients with Acute and Chronic Myocardial Injury.

Authors:  Caelan Taggart; Ryan Wereski; Nicholas L Mills; Andrew R Chapman
Journal:  J Clin Med       Date:  2021-05-26       Impact factor: 4.241

10.  Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy.

Authors:  Christopher Reid; Ahmed Alturki; Andrew Yan; Derek So; Dennis Ko; Jean-Francois Tanguay; Amal Bessissow; Shamir Mehta; Shaun Goodman; Thao Huynh
Journal:  CJC Open       Date:  2020-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.